CQDM, Feldan Therapeutics and Amgen fund development of innovative drug delivery technology to target lung diseases

CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat several disabling pathologies such as chronic pulmonary obstruction and cystic fibrosis. CQDM is providing a grant of $201,512, made possible by the Ministère de l’Économie et de l’Innovation et de l’Énergie (MEIE). This funding, combined with the support of the Quebec company Feldan Therapeutics and the biotech company Amgen, will support the development of new therapeutic options. This project is part of a larger collaboration between the two companies, worth $1,427,757, to expand the potential of Feldan’s unique drug delivery technology.

NewsGuest UserApril 20, 2023BIOOQuébecCQDM, Feldan Therapeutics, Amgen, Drug delivery, lung diseases

The Canadian Cancer Society, CQDM, the Cole Foundation and Oncopole grant close to $8.5 million to four researchers in Quebec to support pediatric cancer research

The Canadian Cancer Society (CCS), CQDM, the Cole Foundation and Oncopole – pôle cancer du FRQS announced, today, grants of $8,485,132 to finance four research projects in Quebec, as part of the Pediatric Cancer Research Initiative.

ECOGENE-21: Drones to promote access to clinical research

ECOGENE-21, a non-profit clinical and academic research organisation dedicated to providing access to innovation for unmet health needs, including rare or severe diseases, successfully completed the first flight demonstrations of the drone delivery process for clinical trials at the Centre of Excellence on Drones (CED) in Alma on September 28.

CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation

During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for this collaborative research project is made possible with the financial support of the ministère de l’Économie et de l’Innovation (MEI) who will be providing $1.36M as part of CQDM’s SynergiQC program.

NewsGuest UserApril 28, 2022CQDM, AltusFormulation, Funding, ocular, blindness

CQDM partners with Neurasic Therapeutics, HBHL and the Louise and Alan Edwards Foundation to fund a non-opioid pain treatment discovery

CQDM is pleased to announce a grant for a collaboration between McGill University, Neurasic Therapeutics, McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative and the Louise and Alan Edwards Foundation.

NewsCatherine LamontagneJanuary 24, 2022CQDM, Neurasic Therapeutics, HBHL, Louise & Alan Edward

CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation

During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for this collaborative research project is made possible with the financial support of the ministère de l’Économie et de l’Innovation (MEI) who will be providing $1.36M as part of CQDM’s SynergiQC program.

NewsCatherine LamontagneDecember 10, 2021CQDM, Biomark, Pfizer, Astrazeneca

CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies

Montréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver tissue to treat liver disease. Founded in 2018 to develop ReLiver®, a highly innovative platform technology which has shown immense promise in animal models to restore liver function, treat complications and accelerate liver regeneration, Morphocell has the potential to revolutionize the treatment of liver failure and save patient lives.

NewsGuest UserJuly 7, 2021CQDM, Morphocell, investment

Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept

MONTREAL--(BUSINESS WIRE)--Giiant Pharma inc. announced today that is closed an additional financing of $750,000 from AQC Capital (AQC) and $500,000 from CQDM for a total of $1.25 million.

NewsGuest UserJune 30, 2021AQC, Giiant Pharma, CQDM, FInancing

Funding for startups in the life sciences sector: Theodorus and CQDM are inviting researchers and entrepreneurs to present their innovative life science projects.

Theodorus and CQDM are looking to accelerate the commercialization of innovative technologies in the life sciences sector.

NewsGuest UserJune 18, 2021CQDM, Theodorus, Financing, startup

nplex-McGill partnership selected by CQDM for a $1M grant to apply next-generation ELISA in drug discovery

McGill University and CQDM announced today that a collaborative project between McGill and nplex biosciences to further develop a highly-scalable protein detection method, termed the “nELISA”, has been selected for funding by CQDM.

NewsGuest UserJuly 23, 2020CQDM, biopharmaceutical, Mesentech, Technology, Drug delivery, bone

CQDM becomes a shareholder of Mesentech to support the validation of a highly promising bone-targeting drug delivery technology

The CQDM is launching its new SynergiQc program, designed to stimulate industrial research in the biopharmaceutical field within academic settings and to create economic benefits for Quebec.

NewsGuest UserJune 22, 2020CQDM, biopharmaceutical, Mesentech, Technology, Drug delivery, bone

CQDM's new SynergiQc program – Financing available for all fields of biopharmaceutical research in Quebec

The CQDM is launching its new SynergiQc program, designed to stimulate industrial research in the biopharmaceutical field within academic settings and to create economic benefits for Quebec.